Track Bright Minds Biosciences Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Bright Minds Biosciences Inc. Common Stock DRUG Open Bright Minds Biosciences Inc. Common Stock in new tab

75.00 USD
EPS
-2.01
P/B
8.94
ROE
-26.98
Beta
-0.19
Target Price
160.78 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 21, 2026
EPS-2.01
Book Value8.39
Price to Book8.94
Debt/Equity0.12
% Insiders11.555%
Estimates
Forward P/E-9.71
Forward EPS-7.72
Target Mean Price160.78

DCF Valuation

Tweak assumptions to recompute fair value for Bright Minds Biosciences Inc. Common Stock (DRUG)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Bright Minds Biosciences Inc. Common Stock Logo Bright Minds Biosciences Inc. Common Stock Analysis (DRUG)

Canada Health Care Official Website Stock

Is Bright Minds Biosciences Inc. Common Stock a good investment? Bright Minds Biosciences Inc. Common Stock (DRUG) is currently trading at 75.00 USD. Market analysts have a consensus price target of 160.78 USD. This suggests a potential upside from current levels.

Earnings Schedule: Bright Minds Biosciences Inc. Common Stock is expected to release its next earnings report on May 21, 2026. The market consensus estimate for Forward EPS is -7.72.

Investor FAQ

Does Bright Minds Biosciences Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Bright Minds Biosciences Inc. Common Stock?

Bright Minds Biosciences Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 21, 2026. The company currently has a trailing EPS of -2.01.

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Exchange Ticker
CNQ (Canada) DRUG.CN
NMS (United States) DRUG

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 14, 2023 0.200000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion